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Cancer can involve non-resolving, persistent inflam-
mation where varying numbers of tumor-associated
macrophages (TAMs) infiltrate and adopt different
activation states between anti-tumor M1 and pro-
tumor M2 phenotypes. Here, we resolve a cascade
causing differential macrophage phenotypes in the
tumor microenvironment. Reduction in TNF mRNA
production or loss of type I TNF receptor signaling
resulted in a striking pattern of enhanced M2 mRNA
expression. M2 gene expression was driven in part
by IL-13 from eosinophils co-recruited with inflam-
matory monocytes, a pathway that was suppressed
by TNF. Our data define regulatory nodes within the
tumor microenvironment that balance M1 and M2
populations. Our results showmacrophage polariza-
tion in cancer is dynamic and dependent on the
balance between TNF and IL-13, thus providing a
strategy for manipulating TAMs.INTRODUCTION
Macrophages are the most-abundant non-tumor-cell-popu-
lating cancers, and their numerical presence is correlated with
poor clinical outcomes (Dannenmann et al., 2013; Gajewski
et al., 2013; Galon et al., 2013; Zhang et al., 2012). The large
numbers of macrophages in tumors raises a simple but unan-
swered question: what are macrophages doing in tumors? One
possibility is macrophages seed tumors to repair tissue they
detect as damaged. In cancer, malignant tissue looks like
‘‘self,’’ thereby escaping detection by immune cells. It therefore
is hardly surprising macrophages are recruited to tumors if they
are performing their normal ‘‘cleanup’’ functions. In doing so,
macrophages may aid and abet an enemy within as proposed1902 Cell Reports 12, 1902–1914, September 22, 2015 ª2015 The Aby Dvorak in the ‘‘wounds that don’t heal’’ model (Bissell and
Hines, 2011; Dvorak, 1986).
Given that clinical and mouse model data frequently correlate
macrophages with pro-tumor activities, several different tactics
have been used to deplete or interfere with macrophage viability
or recruitment including tyrosine kinase inhibitors or monoclonal
antibodies targeting the colony-stimulating factor 1 receptor
(CSF-1R), CD11b, or antibodies targeting CCL2, a chemokine
for monocyte recruitment to tumors (Ahn et al., 2010; Bonapace
et al., 2014; Pyonteck et al., 2013; Ries et al., 2014). However, the
anti-macrophage activity of these drugs is not limited to macro-
phages in tumors. Macrophages are required for normal homeo-
static functions and populate all tissues of the body. Therefore,
gross targeting of monocytes and/or macrophages is likely to
cause toxicities in tissues dependent on macrophages such as
the gut, lungs, and heart (Epelman et al., 2014). Unanticipated
side effects such as tumor rebound when drug therapy ceases
have been reported (Bonapace et al., 2014). Macrophages are
also critical for cell corpse disposal and tissue repair after
chemotherapy, irradiation, or surgery. In these therapies, macro-
phages have time-dependent pro- and anti-tumor functions
(De Palma and Lewis, 2013; Klug et al., 2013; Ma et al., 2013;
Nakasone et al., 2012; Predina et al., 2013). Collectively, target-
ing specific pro-tumor macrophage functions rather thanmacro-
phages per se could be a valuable addition to standard-of-care
therapies.
Macrophages and dendritic cells are ‘‘plastic’’ because
their inflammatory mediator production is tailored for respon-
siveness to specific environmental cues (Murray and Wynn,
2011a; Wynn et al., 2013). Macrophages alter their effector and
defense mechanisms across a spectrum between ‘‘M1’’ pro-
inflammatory phenotypes—characterized by destructive anti-
intracellular pathogen free radical and inflammatory cytokine
production—and ‘‘M2’’ states—displayed by tissue-resident
macrophages and macrophages encountering worms and fungi
(Murray et al., 2014; Wynn et al., 2013). M2 macrophages ex-
press genes involved in tissue repair and resolution and haveuthors
immunosuppressive and immunoregulatory properties (Murray
and Wynn, 2011b). In resolving inflammation, M1 macrophages
can convert into M2macrophages to restore tissue homeostasis
and integrity during and after removal of the inciting entity (Wynn
et al., 2013).
By contrast to resolving inflammation, chronic cancer-associ-
ated inflammation is a non-resolving response because of the
persistence of malignant cells (Biswas and Mantovani, 2010;
Nathan and Ding, 2010). An emerging body of clinical and exper-
imental evidence links activated M1-like macrophages and
cytotoxic CD8+ T cells to improved overall outcomes in cancer
and cancer therapy, compared to poorer outcomes in cancers
harboring numerous macrophages and low numbers of CD8+
T cells (Fridman et al., 2012; Gajewski et al., 2013; Predina
et al., 2013). Macrophages with M2 gene expression are thought
to be detrimental to anti-cancer therapies, and manipulation of
their phenotype is considered key to the development of suc-
cessful immunotherapies (De Palma and Lewis, 2013; Hanahan
and Coussens, 2012; Qian and Pollard, 2010; Ruffell et al.,
2012). Although actively debated, the mechanisms associated
with macrophage polarization in cancer remain controversial.
Most important is the absence of a coherent framework for un-
derstanding the signaling pathways controlling macrophage
polarization and how polarization is regulated across time and
space within a tumor. Here, we used a diverse range of tumor
types, a systematic isolation strategy, and genetic platforms to
dissect the signals regulating tumor-associated macrophage
(TAM) polarization. Our results elucidate how mixtures of M1
and M2 can be simultaneously present and how these pheno-
types change in tumors. We show M2 TAMs are enhanced
by local amounts of IL-13 and antagonized by TNF. We found
TNF is a key cytokine capable of blocking M2 gene expression
in macrophages in general, and these effects of TNF on M2
genes are context dependent.
RESULTS
Macrophage Isolation Procedure from Diverse Tumor
Types Does Not Alter Inflammatory Gene Expression
To gain insight into macrophage polarization in solid tumors, we
compared macrophage infiltration in diverse genetic, anatomic,
and orthotopic solid tumor models, including neuroblastomas,
retinoblastomas, osteosarcomas, and the widely used implant-
able thymoma (EG7) model. Given themajority of TAMs originate
from recruited CD11b+ blood monocytes (Cortez-Retamozo
et al., 2012; Franklin et al., 2014; Movahedi et al., 2010; Shand
et al., 2014), we optimized a TAM isolation procedure based
on tissue digestion and CD11b+ magnetic bead isolation to cap-
ture the largest fraction of TAMs (Figure S1A). CD11b+ enrich-
ment captures all monocytes and macrophages in the tumor
microenvironment, in addition to neutrophils (discussed below),
and avoids plastic enrichment steps (Biswas et al., 2006), which
we found caused a decrease in the expression of numerous
inflammatory mRNAs following TAM adherence (Figure S1B).
To determine whether the isolation procedures themselves per-
turbed polarization-associated gene expression, we developed
an in vitro 3D tumor-macrophage co-culture system where
bone-marrow-derived macrophages are introduced into wellsCell Repcontaining a single tumor ‘‘sphere’’ and migrate inside (Fig-
ure S1C). We isolated the TAMs using the same tissue digestion
and purification method described above and found few differ-
ences in M1 or M2 genes between the tumor or non-tumor mac-
rophages. Importantly, gene expression linked to contaminating
endotoxin such as TNF or IL6 was not increased by digestion
(Figures S1D and S1E).
In CD11b+ TAMs, we detected high expression of TLR2 and
CD14 mRNAs whereas mRNAs encoding other TLRs and the
IL-1R had low or undetectable expression (Figure S2A). To
further determine whether TAM isolation itself triggered inflam-
matory gene expression, we compared the CD11b+ fractions
from TAMs (EG7) isolated from control or MyD88-deficient
mice where all TLR and IL-1R signaling (except TLR3) is ablated.
Because TLR3 was not expressed in TAMs (Figure S2A), the
absence of MyD88 signaling should eliminate TAM TLR/IL1R
signaling and provide a sensitive readout of exogenous LPS
contamination. However, the inflammatory gene signature in
tumors isolated from MyD88-deficient mice revealed few differ-
ences compared to controls for most MyD88-dependent genes
(Figures S2B and S2C). The main differences observed in
MyD88-deficient CD11b+ TAMs compared to controls were in
mRNAs encoding members of the IL-12 family (IL-12b, IL-12a,
IL-27, and IL-23) and G-CSF (Figure S2B).
Collectively, we concluded our isolation procedure caused
minimal experimental-derived perturbation of inflammatory
gene expression. In the absence of MyD88, inflammatory gene
expression stayed intact with the exception of IL-12 family mem-
bers, the opposite of the conclusions drawn from in vitro adeno-
virus-mediated IKK manipulation (Hagemann et al., 2008). The
underlying reasons for the specificity of MyD88 signaling toward
such a restricted set of mRNAs in our in vivo model remain to
be established but are similar to the narrow effects of MyD88
disruption in humans (Alsina et al., 2014). Therefore, factors other
than TLR or IL-1R signaling were responsible for regulating M1
gene expression in TAMs.
TAMs Express M1- and M2-Associated Genes
We used microarray profiling and qRT-PCR of CD11b+ TAMs to
capture information on whether distinct tumor types influence
global TAM gene expression. Regardless of their origin, we
found high expression of M1-associated inflammatory genes in
CD11b+ TAMs (Figures 1A and S2D). The inflammatory signature
of the highest expressed genes was concordant between TAMs
independent of tumor type, arguing mechanisms common to the
tumor microenvironment were responsible for driving the inflam-
matory phenotype. Closer inspection of the CD11b+ TAM array
data showed expression of numerous M2 signature mRNAs
(Arg1, Mrc1, Chi3l3, Socs2, and Ccl24; Figure 1A). Furthermore,
the CD11b+ TAM fraction was ARG1+ relative to separately puri-
fied tumor cells (Figure 1B). These data suggest both M1 andM2
gene expression signatures were simultaneously present within
the CD11b+ TAM fraction. Given reports claiming TAMs are M2
(Biswas and Mantovani, 2010) or M1 (Franklin et al., 2014) or
have more-complex phenotypes (Biswas et al., 2006; Colegio
et al., 2014; Elpek et al., 2014; Chittezhath et al., 2014; Murray
et al., 2014), we next investigated the relationship between
M1-M2 TAMs in more detail.orts 12, 1902–1914, September 22, 2015 ª2015 The Authors 1903
Figure 1. Cooperative MyD88-TNF Signaling Drives Expression of M1/M2 Genes in TAMs
(A) M1- and M2-associated gene expression in TAMs isolated from three tumor models (Glio, glioma; Neuro, neuroblastoma; Thymo, thymoma) and analyzed by
microarray. Signal intensities are shownwith the rank among 45,037 probe sets (in N-TAMs). Color code represents high (yellow) to low (blue) intensities. Data are
representative of the log2 signal intensities (n = 3 per TAM type).
(B) Immunoblot analysis of ARG1 expression in CD11b+ andCD11b fractions isolated fromEG7 thymomas or gliomas grown inArg1flox/flox;Tie2-cre (Arg1KO) and
WT (Arg1flox/flox littermates) mice.
(C–E) qRT-PCR of EG7 TAM RNA isolated from WT, TNFRKO, Myd88DH, or DKO mice.
Each dot represents the expression values from individual mice from at least two experiments with the black line representing the mean. The error bars represent
SEM. Statistical significance was calculated using two-tailed Student’s t test and is indicated by *p < 0.05, **p < 0.01, and ***p < 0.001.
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Type 1TNFRSignaling Is a Central Negative Regulator of
M2 TAMs
As discussed above, MyD88-deficient TAMs revealed few differ-
ences compared to controls for inflammatory genes (Figures
S2B and S2C). Reasoning redundant inflammatory pathways
might cooperate with MyD88 to promote the TAM signature,
we focused on TNF because mRNAs encoding TNF, TNFR1
(TNFRp55, encoded by Tnfrsf1a), and TNFR2 (encoded
by Tnfrsf1b) were highly expressed in TAMs based on our micro-
array data and TNF activates NF-kB to drive inflammation,
potentially overlapping with, or compensating for, the MyD88
pathway. We therefore used mice lacking TNFR1 (called
TNFRKO) as a source of TAMs. Coincident with these studies,
we also generated mice in which type I TNF receptor, TLR, and
IL-1R signaling were collectively ablated to generate a more-
comprehensive view of potential signaling redundancies by
NF-kB-activating receptors. To do this, we used TNFR1 and
Myd88DH TNFRKO double knockout mice (called DKO). The
global MyD88 knockout has multiple effects in non-hematopoi-
etic cells (Yu et al., 2014), and we therefore generated mice lack-
ing MyD88 in the hematopoietic compartment (called Myd88DH)
using the Tie2-Cre deleter (El Kasmi et al., 2008). The macro-
phage/neutrophil-specific LysM-Cre deleter was also tested;
however, the low degree of deletion of MyD88 protein in TAMs
precluded the use of these mice in our experiments (Figure S2E).
TAMs lacking both MyD88 and TNFR1 showed substantial or
complete reduction in most M1 inflammatory gene expression
(Figure 1C) that correlated with a concomitant increase in tumor
size (Figures S3A and S3B) that was intrinsic to macrophages as
transplantation of tumors with BMDMs from control or TNFRKO
mice into CCR2-deficient animals (which lack the majority of
TAMs) recapitulated the increases in tumor size (Figures S3C–
S3E). TNF mRNA expression was reduced in DKO TAMs, sug-
gesting the ablation of both MyD88 and TNFR signaling disrup-
ted feedforward inflammatory loops driving M1 gene expression
via TNF (Figure 1D). Thus, TLR/IL-1R and TNF signaling collec-
tively enforced a cooperative pro-inflammatory pathway respon-
sible for the M1-like TAM signature, and these data likely
accounted for the limited phenotype of the MyD88-deficient
mice; TNF signaling is redundant with TLR/IL-1R signaling in
TAMs.
By contrast to the reduction in M1 gene expression in DKO
mice, M2 gene expression in TAMs from TNFRKO, DKO, and
to a certain extent from Myd88DH mice showed a remarkable
signature (Figure 1E). TAMs isolated from DKO mice showed
increased production of M2-associated mRNAs, suggesting
that MyD88 and TNF signaling collectively masked or actively
repressed M2 gene expression. In MyD88DH TAMs, the TNF
mRNA was among the strongest reduced transcripts. We
therefore hypothesize the effects of MyD88 deletion in TAMs
on M2-associated genes expression rely on reduced signaling
downstream TNFR1 similar to TNFRKO TAMs.
M2 Gene Expression Is Enriched in CD11b+, Ly6C,
MHCII+ TAMs from TNFRKO Mice
An issue stemming from the above experiments concerned
which cells in the tumor microenvironment were expressing the
M2markers. To address this, we notedmanyMyD88-dependentCell Repgenes in the CD11b+ fraction were enriched in the Ly6G+ neutro-
phil fraction (Figure S3F). These data prompted us to modify our
TAM isolation procedure (Figures 2A and 2B) to more specifically
isolate different TAM fractions (Kratochvill et al., 2015). We built
upon methodologies (Movahedi et al., 2010; O’Sullivan et al.,
2012) where the CD11b+ fraction was sub-divided into four pop-
ulations: neutrophils (Ly6G+ and CD11b+), the TAMs directly de-
scended from blood monocytes called TAM-A (CD11b+, Ly6Chi,
and MHCII), TAM-B (CD11b+, Ly6C+, and MHCII+) and TAM-C
(CD11b+, Ly6C, and MHCII+). TAM-A, -B, and -C originated
from monocytes because each of these cells was absent in
Ccr2/mice (Figure 2A) (Cortez-Retamozo et al., 2012; Franklin
et al., 2014; Shand et al., 2014). Furthermore, results from tracing
relationships between monocytes and their progeny suggests
‘‘mature’’ TAM-C are descended from TAM-A (Movahedi et al.,
2010), in a process similar to other inflammatory models where
local macrophages originate from blood monocytes seeding an
inflammatory site (Bain and Mowat, 2014; Bain et al., 2013).
Furthermore, the CD11b+ population contains cells consistent
with their identity as eosinophils (Eos, discussed below) distin-
guished from monocytes by the degree of Ly6C expression
(Figures 2A and 2B). Consistent with other data showing macro-
phage cell surface phenotypes change with maturation from
monocytes (Movahedi et al., 2010; O’Sullivan et al., 2012), we
found increased F4/80 and CX3CR1 expression on mature
TAM-B and TAM-C relative to the monocyte-rich TAM-A fraction
(Figure 2C).
Coincident with our flow cytometry protocol, we used ortho-
topic tumor models as a reproducible experimental standard
that can be transplanted into any mouse on a C57BL/6 back-
ground (EG7, Lewis lung carcinoma, and B16 melanoma).
When we compared the CD11b+ populations in each model, a
gradient of non-monocytic Ly6C+ infiltration was observed.
EG7 tumors had high numbers of non-monocytic Ly6C+whereas
B16 tumors were devoid of these cells (Figure 2D). As described
later, this heterogeneity provided a platform to test the contribu-
tion of eosinophils to TAMpolarization phenotypes.We therefore
sorted the TAM-A and TAM-C fractions from EG7-bearing mice
and subjected each fraction to microarray analysis. We found
that the expression of nearly all M2 marker mRNAs were (1) en-
riched in the TAM-C fraction relative to TAM-A and (2) increased
in the absence of type I TNFR signaling (Figure 2E). These data
suggest TNF is an in vivo repressor of M2 signaling in TAMs.
TNF Blocks STAT6-Dependent M2 Gene Expression in a
Gene-Specific Manner
Next, we asked whether TNF was a general inhibitor of M2 gene
expression (Figure 3A). We generated bone-marrow-derived
macrophages (BMDMs) with recombinant CSF-1 and stimulated
them with IL-4 and IL-13 to induce M2 gene expression via
STAT6, with or without recombinant TNF. We measured M2
gene expression by qRT-PCR and found three patterns (Figures
3A–3C). First, mRNAs encoding Retnla (also called FIZZ1), Mgl2,
and Mrc1 (mannose receptor) were induced by IL-4 and IL-13 as
expected but repressed by TNF (Figure 3A). Arg1 mRNA was
also induced by IL-4 and IL-13 as expected, but not blocked
by TNF (Figure 3B). The final group of mRNAs encoded the M2
chemokines CCL17 and CCL22, which were induced by TNF,orts 12, 1902–1914, September 22, 2015 ª2015 The Authors 1905
Figure 2. MyD88 and TNFR1 Signaling Suppresses
M2 Gene Expression in TAMs
(A) Gating strategy of TAM populations A (red ellipse), B
(orange ellipse), and C (green ellipse) as well as tumor-
infiltrating eosinophils (Eos, purple square) and double
negative (DN) cells for sorting experiments comparing EG7
TAMs from WT and Ccr2/ mice.
(B) Schematic representation of TAM development from
TAM-A to TAM-C.
(C) F4/80 and CX3CR1-GFP expression in EG7 TAMs iso-
lated from WT and CX3CR1-GFP mice in TAM fractions
as shown in (A) and (B). Data are representative histograms
of three (F4/80; n = 10) or one (CX3CR1-GFP; n = 3)
experiments.
(D) TAM fractions in macrophages gated as shown in (A)
isolated from different transplantable tumor models. Blots
are representative for at least two experiments where each
experiment used at least five mice per tumor type.
(E) Transcriptome analysis of EG7 TAM populations A
and C derived from WT, TNFRKO, Myd88DH, or DKO mice.
Depicted values of M1- and M2-associated genes are
heatmaps arranged by log2 signal intensities (n = 2 per
genotype).
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Figure 3. TNF Signaling Blocks IL-13-Derived M2 Polarization
(A–C) qRT-PCR analysis of BMDMs left unstimulated or treated with a cocktail of IL-4 and IL-13 in combination with or without TNF for the times indicated. Data
are the mean expression values (n = 2) and are representative for one out of two experiments.
(legend continued on next page)
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but not by IL-4 and IL-13, the opposite phenotype to TAMs
where expression of each mRNA is enhanced in the absence
of TNFR1 signaling (Figures 1E and 2E). When viewed collec-
tively, these data showed the negative effects of TNF on M2
gene expression we observed in the tumor microenvironment
can only in part be translated to in vitro experiments using
BMDMs. Importantly, TNF blocked M2 expression in a gene-
and macrophage-type-specific way. The latter point prompted
us to return to investigate in more detail the signaling
events that established the M2 phenotype within the tumor
microenvironment.
STAT6 Is Required for TAM M2 Gene Expression
Recent results showed lactate and hypoxia are important factors
in amplifying M2-associated gene expression, especially Arg1
(Colegio et al., 2014; El Kasmi et al., 2014). However, IL-4 and
IL-13, via STAT6 phosphorylation, are widely accepted as the
major drivers of M2 gene expression. We found TAM-A and
TAM-C from EG7 TAMs expressed the IL-4Ra and IL-13Ra
(Figure 3D) consistent with the ability of these cells to activate
STAT6. We used the orthotopic transplant system in Stat6/
mice on a pure C57BL/6 background and generated TAM frac-
tions. We found overall M2 gene expression for six targets and
expression of PD-L2 (Huber et al., 2010) was reduced or elimi-
nated in the absence of STAT6 (Figures 3E and 3F). However,
these data also allowed us to test the STAT6-independent
expression of individual genes. Consistent with recent data (Co-
legio et al., 2014), Arg1 mRNA expression was partially affected
by the loss of STAT6, indicating other pathways regulate Arg1,
whereas mRNAs encoding Retnla and Ccl24 were substantially
reduced (Figure S4A). Importantly, the amounts of surface IL-
4Ra or IL-13Ra were unaffected by genetic perturbation of the
STAT6 or TNFR pathways (Figure 3G). These data are consistent
with amodel wheremultiple factors collaborate to provide anM2
permissive environment; lactate/hypoxia are likely one signal
collaborating with STAT6 but work in a gene-specific way (Cole-
gio et al., 2014; El Kasmi et al., 2014).
IL-13 Amplifies M2 TAMs and Is Blocked by TNF
Given our data showed an important contribution of IL-4- and IL-
13-activated STAT6 to TAMM2 gene expression, we next asked
whether we could detect IL-13 or IL-4 in the tumor environment.
We found elevated amounts of IL-13 in bulk TAMs isolated from
TNFRKO mice, raising the possibility that IL-13 expression was
suppressed by TLR and/or TNF signaling (Figure 4A). IL-4 and
IL-13 are produced by many immune cells including T cells,
ILCs, neutrophils, and even macrophages under certain condi-
tions. Unlike recent findings showing neutrophils are a central(D) Flow histograms of IL-4Ra and IL-13Ra expression in EG7 TAM populations A
in gray.
(E) qRT-PCR ofM2 genes EG7 TAMpopulations A andC isolated fromWT and Sta
experiments with the black line representing the mean.
(F) The expression of theM2marker PD-L2 in EG7 TAMpopulations A and Cwas a
as median fluorescence intensity (MFI) (n = 3) and representative flow analysis in
(G) IL-4Ra and IL-13Ra expression in EG7 TAM populations A and C analyzed by
Data are shown as MFI (WT; Stat6KO: n = 4; TNFRKO: n = 3) and represent one o
Statistical significance was calculated using a two-tailed Student’s t test and is ind
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could not detect IL-13 in tumor infiltrating Ly6G+ neutrophils
(Figure 4B). Similarly, we found T cell numbers in orthotopic
tumors were very low and unchanged in the TNFRKO mice, sug-
gesting T cells were not a major source of IL-13 in our models
(Figures S4B–S4F). However, IL-13 mRNA expression was
enriched in non-monocytic CD11b+ Ly6C+ cells from TNFRKO
mice with characteristics of eosinophils (Lee et al., 2012) (Fig-
ures 4B and 4C). The eosinophil-like cells expressed variable
amounts of SiglecF and had the cytological appearance of
eosinophils (Figures 4C and 4D). However, they did not express
CCR3, an eosinophil and red pulp macrophage marker as
defined by the ImmGen database, which may be downregulated
in the tumor microenvironment. These cells are referred to here-
after as eosinophils. Neutralization of IL-13 with a monoclonal
antibody (mAb) in EG7-bearing TNFRKO mice showed partial
reduction of M2 gene expression, consistent with the idea that
local IL-13 is required in part to increase TAM M2 polarization
(Figure 4E).
These data suggested TNF signaling negatively regulates two
steps in the tumor microenvironment. First, TNF directly blocked
specific sets of M2 genes. Second, TNF suppressed IL-13
expression from eosinophils and thus prevented production of
a key M2-activating cytokine; the net effect was local reduction
in M2 gene expression. If this model is valid, then we should be
able to correlate eosinophil numbers in tumors with M2 gene
expression. To test this prediction, we used the orthotopic trans-
plant system where EG7, LLC, and B16 tumors were infiltrated
with different amounts of eosinophils, such that EG7 had the
most and B16 tumors the least (Figures 2D and 5A). Consistent
with our model, the number of eosinophils correlated with the
amount of IL-13 mRNA detected in the different tumor models
in TNFRKO mice (Figure 5B). When we analyzed gene expression
in each tumor, a correlation in M2 expression from EG7 > LLC >
B16was observed in the TNFR-deficient mice (Figure 5C). These
data therefore define, in an in vivo model system, that TNF
signaling is a negative regulator of both IL-13 production and
responsiveness of macrophages to IL-13.
Anti-TNF drugs have been successfully used for chronic
inflammation for two decades. The mechanism of action of
anti-TNF drugs is to block TNF, limiting feedforward inflamma-
tion. However, based on our data, a linked mechanism could
be the promotion of M2 macrophages. To test this hypothesis
in cancer, we used etanercept, a soluble TNFR that partially
limits TNF bioavailability. Administration of etanercept to
mice bearing EG7 tumors caused a relative increase in IL-13
as well as M2 gene expression in CD11b+ TAMs that did not
reach the magnitude of the effect seen in the completeand C, representative of two experiments (n = 10). Unstained control is shown
t6KOmice. Data are the expression values from individual mice (nR 7) from two
nalyzed by flow cytometry isolated fromWT and Stat6KOmice. Data are shown
TAM-C.
flow cytometry as shown in (D) isolated from WT, TNFRKO, and Stat6KO mice.
ut of three experiments.
icated by *p < 0.05, **p < 0.01, and ***p < 0.001. The error bars represent SEM.
uthors
Figure 4. Tumor-Infiltrating Eosinophil-
Derived IL-13DrivesM2 Expression in TAMs
(A and B) qRT-PCR analysis of IL-13 production in
EG7 TAM unsorted (A) or sorted for TAM sub-
populations as depicted in Figures 2A and 2B.
Values from individual mice (A: nR 21; B: nR 10)
from at least two experiments are shown. Data in
(B) were normalized to eosinophils (Eos). The error
bars represent SEM.
(C) SiglecF expression analyzed by flow cytometry
in TAM subpopulations gated as shown in Fig-
ure 2. Plots are representative for three experi-
ments.
(D) H&E stained cytospin slides of EG7 TAM
populations (403 magnification). Pictures shown
are representative of two experiments (n = 4).
(E) qRT-PCR analysis of CD11b+ EG7 TAMs
derived from control IgG1 or anti-IL-13 antibody-
treated TNFRKO mice (n R 5). Mean expression
values from one of two experiments are shown.
The error bars represent SEM. Statistical signifi-
cance was calculated using a one-way ANOVA (B)
or two-tailed Student’s t test (A and E) and is
indicated by *p < 0.05, **p < 0.01, and ***p < 0.001.TNFRKO mice as expected based on previous experiments
comparing etanercept and potent antibody-based TNF
blockers (Vos et al., 2012) (Figures 6A and 6B). Consistent
with data showing Arg1 gene expression is regulated by via
multiple pathways, Arg1 mRNA was not increased by etaner-
cept treatment (Figure 6C). Therefore, TNF inhibition is linked
to the promotion of M2 macrophages, which may contribute
to the salutary effects of anti-TNF drugs in colitis and rheuma-
toid arthritis but may also promote a tumor-permissive M2
environment in cancer.Cell Reports 12, 1902–1914, SepDISCUSSION
Our experiments provide a conceptual
framework for explaining why both M1
and M2 TAMs have been observed in
cancer: the quantity of macrophages at
either end of the polarization spectrum
depends on the balance between IL-13
(and possibly IL-4) delivery by eosinophils
and the overall amount of TLR, IL-1R, and
TNFR signaling. Therefore, we predict
cancers associated with high amounts
of endogenous commensal- and path-
ogen-derived molecules, DAMPs, and
TNF such as colon cancer will trend to
the M1 end of the spectrum because
the STAT6-dependent M2 response will
be suppressed. Conversely, we predict
tumors with low relative inflammation
such as at sterile sites like breast and
head and neck tumors or developmental
tumors of childhood will have higher
relative numbers of M2 macrophages
because the TNF: M2 balance shifts infavor of M2 TAMs. This balance is likely further controlled by
temporal and spatial variables within the microenvironment.
The key finding of our work is that TNF negatively regulates
M2 gene expression both in vivo and in vitro. We established
TNF did not inhibit all M2 gene expression. Instead, TNF tar-
geted subsets of genes. These data argue for a model where
downstream signals from the type I TNFR, such as NF-kB,
act in a gene-specific way. Our data can be used to explain
phenotypes of knockout mice where unanticipated polarization
switching was observed but could be correlated with local TNFtember 22, 2015 ª2015 The Authors 1909
Figure 5. M2 Gene Expression in TNFRKO TAMs Correlates with
Tumor-Infiltrating Eosinophils
(A) Frequency of tumor-infiltrating eosinophils in three different tumor models
(EG7, LLC, and B16) in WT and TNFRKO mice gated as in Figure 2A. Data are
values from individual mice (nR 6) from at least two independent experiments
per tumor model. Cell frequencies are shown as percent Ly6C+/MHCII cells
of all CD11b+Ly6G cells. The error bars represent SEM.
(B and C) qRT-PCR analysis of CD11b+ TAMs isolated from different tumor
models in WT and TNFRKO mice as in (A) (nR 5).
Data are the mean expression values normalized to the corresponding
WT TAMs in each tumor model and represent values from individual mice
from at least two independent experiments per tumor model. The error bars
represent SEM.production. For example, CD14-deficient mice have greatly
enhanced M2-driven granulomatous response to schistosome
eggs trapped in the liver. In these granulomas, macrophages
express high amounts of M2 genes Retnla, Arg1, and Chi3l3
expression relative to controls (Tundup et al., 2014). One
explanation for the phenotype is loss of CD14, an essential
surface component of TLR signaling, will lead to defects in
local TNF production and enhanced M2 responses. Another
example of chronic inflammation linked to the inverse balance
between TNF and M2 macrophages is obesity. In lean adipose
tissue, M2-like tissue resident macrophages interdigitate
between fat cells, whereas in obesity, excess fat suppresses
M2 macrophages and is associated with increased TNF
(Lumeng et al., 2007; Weisberg et al., 2003; Xu et al., 2003).1910 Cell Reports 12, 1902–1914, September 22, 2015 ª2015 The AHowever, when TLR4 signaling is genetically ablated in
obesity, M2-associated macrophage genes increase, and this
phenotype paralleled a decline in TNF (Orr et al., 2012). There-
fore, a general prediction from our studies is many inflamma-
tion-linked polarization phenotypes might be dictated by
an inverse relationship between TNF and signals driving M2
polarization (IL-4 and IL-13); increased TNF will block M2 po-
larization in a gene-specific way, depending on quantity,
time, and spatial availability. The conceptual advance made
here to inversely link M2 polarization and TNF may also help
explain why cytotoxic therapy is linked to M1 macrophages
as the necrotic and apoptotic death of large numbers of tumor
cells releases DAMPs (Klug et al., 2013), which through local
TNF generation, will suppress IL-13 and IL-4 from eosinophils
and thus also suppress STAT6-dependent M2 TAMs. Finally,
we suggest anti-TNF drugs might also work through the com-
bined effects of suppressing a pro-inflammatory signal that
concomitantly causes a rise in M2 macrophages. Indeed,
anti-TNF drugs promote changes in macrophage phenotype,
and this effect is proportional to TNF neutralization (Vos
et al., 2011, 2012). We used etanercept, a soluble TNFR, which
was noted to have the weakest effect of macrophage pheno-
typic changes. Our in vivo data confirmed this finding, as eta-
nercept caused increases in TAM M2 gene expression, which
were less than that observed in the complete TNFR1-deficient
mice. Therefore, we consider an important direction stemming
from our work will be to reconsider the mechanistic actions of
TNF blockers. For example, anti-TNF therapy causes tubercu-
losis reactivation, a phenotype attributed to removal of TNF
(Flynn et al., 1995). However, because M2 macrophages are
permissive to TB (Potian et al., 2011), we predict part of the
reason anti-TNF drugs are contraindicated for TB-infected
patients is linked to elevations of M2 macrophages.
A previous study using an ovarian cancer model claimed
NF-kB signaling was required for maintaining the expression of
M2 genes (Hagemann et al., 2008). These results are difficult
to interpret for several reasons. NF-kB signaling is necessary
for most inflammatory gene expression. In Hagemann et al.
(2008), inhibition of NF-kB by manipulating IKKb caused in-
creases in IL-12p40 and iNOS expression, the opposite of
what one would expect, as expression of both genes requires
contributions from NF-kB complexes for optimal expression
(Farlik et al., 2010; Sanjabi et al., 2000; Sen and Smale, 2010;
Zhou et al., 2004). In our in vivo studies, IL-12p40 expression is
dependent on MyD88 in TAMs residing in the tumor microenvi-
ronment, arguing for a positive role of NF-kB activation down-
stream of TLR signaling. The conclusions drawn by Hagemann
et al. derived from an experimental system where adenoviruses
were used to transfer dominant-negative versions of IKKb or Cre
recombinase into CSF-1-generated BMDMs. As the effects of
viral infection in the absence of functional NF-kB signaling in
the experimental arms were unaccounted for, the claims of
this study remain difficult to interpret and differ from most other
findings in the field.
Our data clearly show eosinophil-derived IL-13 is one factor
provoking M2 polarization. Therefore, local IL-13 will enhance
M2 polarization, depending on how much TNF is present. IL-4
may also be a key factor in TAM M2 polarization, but we founduthors
Figure 6. Treatment with the Anti-TNF Drug
Etanercept Enhances IL-13 and M2-Associ-
ated Gene Expression in TAMs
qRT-PCR analysis of CD11b+ EG7 TAMs isolated
from PBS- (nR 17) or etanercept- (nR 18) treated
WT mice compared to TAMs from TNFRKO mice
(nR 11). Data represent individual mice from three
experiments normalized to the corresponding
mean PBS-treated WT TAMs per experiment. The
error bars represent SEM. Statistical significance
was calculated using a two-tailed Student’s
t test and is indicated by *p < 0.05, **p < 0.01, and
***p < 0.001.IL-4 expression difficult to reliably detect, consistent with obser-
vations made in other systems and with different IL-4 reporter
mice (Liang et al., 2012). Our data are consistent with recent
studies in helminth infections showing neutrophils are the source
of M2-enhancing cytokines and that eosinophils produce IL-4
and IL-13 in beige fat-associated macrophages (Chen et al.,
2014; Qiu et al., 2014). One unexpected facet of our data was
the inhibitory effect of TNF on IL-13 production from eosinophils,
as the loss of type I TNF signaling greatly enhanced eosinophil
IL-13 production. Therefore, an eosinophil-intrinsic signaling
pathway from the TNFR blocks IL-13. Indeed, a recent study
has shown eosinophils have potent anti-tumor properties when
activated and co-transferred with cytotoxic T cells (Carretero
et al., 2015). In this study, the eosinophils were pre-treated
with TNF and IFN-g and co-transferred with activated OT1
T cells, which can make TNF. Therefore, understanding the bal-
ance of signals that control TNF, IL-13, eosinophils, and TAMs
may be important in understanding andmodulating inflammation
in addition to the potential for rational manipulation of macro-
phage polarization in the tumor microenvironment.
EXPERIMENTAL PROCEDURES
Mice
C57Bl/6, Myd88flox/flox, Stat6/, B6.Cg-Tg(Tek-cre)1Ywa (Tie2-Cre), Ccr2/,
Cx3cr1GFP, and Lyz2tm1(cre)Ifo/J (LysM-Cre) mice were obtained from Jackson
Laboratories. TNFR1 knockout mice (Tnfrsf1a/) were a gift from V. Redecke
(St. Jude Children’s Research Hospital). Myd88/ mice were obtained from
D. Green (St. Jude Children’s Research Hospital) and were originally a gift
from S. Akira (Osaka University). Arg1flox/flox mice have been described else-
where and were crossed to Tie2-Cre mice (El Kasmi et al., 2008). Littermate
controls that were Cre negative or positive were used. The above-mentioned
mouse lines were crossed to a pure C57Bl/6 background (greater than ten
generations) in house or as supplied from Jackson Laboratories. C57Bl/6 con-
trol animals were bred and housed in the same rooms at St. Jude Children’s
Research Hospital. Where intercrossing was performed, littermate controls
were used where feasible. All mouse breeding, husbandry, and tumor modelsCell Reports 12, 1902–1914, Sepwere performed according to established guide-
lines for laboratory animal use. Th-MYCN trans-
genic (Weiss et al., 1997), Chx10-Cre, Rbflox/flox;
p107/; p130flox/flox, and Mdmx-tg; Rbflox/flox;
p107/; Chx10-Cre mice were used as sources
of retinoblastomas, and Rbflox/flox; p53flox/flox;
Osx-Cre+ mice were used to generate osteosar-
comas. All mice used in this study were co-housed
by sex and were bred and used within the AnimalResource Center according to protocols approved by the IACUC at St. Jude
Children’s Research Hospital.
Tumor Models—In Vivo
Glioma
Gliomas were engineered from granule neural progenitors purified from cere-
bella of Tp53/, Cdkn2c/, Math1-GFP 5- to 7-day-old pups, transduced
with retroviruses expressing an HER2/Neu mutant ERBB2 V695A and the
red fluorescent protein dsRed (MSCV-ERBB2V695A-IRES-dsRed). 1 3 103
GFP-RFP double-positive cells were implanted in the cortices of CD1 nude
mice (Kawauchi et al., 2012) for 69–77 days. 33 106 tumor cells from dissoci-
ated gliomas were injected subcutaneously into the flank of recipient C57BL/6
mice for TAM isolation.
Thymoma
EG7 lymphoma line originating from the thymus (EL4, stably expressing OVA
protein) was injected subcutaneously into the flank of recipient mice (3 3
106 cells/mouse). Gliomas and thymomas were harvested from mice between
1.5 and 2 weeks post-transplant.
Neuroblastoma
Spontaneous neuroblastomas detected by ultrasound were collected from the
peritoneum of Th-MYCN transgenic (tg) mice.
Retinoblastoma
Spontaneous retinoblastomas were collected behind the eye from either
Rbflox/flox; p107/; Chx10-Cre or MDMX-tg; Rbflox/flox; p107/; Chx10-Cre
mice.
Osteosarcoma
Spontaneous osteosarcomas were collected from Rbflox/flox; p53flox/flox; Osx-
Cre+ mice. LLC and B16 tumor models were used as described (Haverkamp
et al., 2014).
Media and Reagents
Tumor Digestion Media
Tumor digestion media (TDM) was 5 mg DNase I (Worthington), 12.5 mg
collagenase P (Roche), 12.5 mg collagenase/dispase (Roche), 100 ml B27
(Invitrogen), and 50 ml N2 (Invitrogen), made to 5 ml with Neural Basal medium
(Invitrogen), followed by 0.22 mm filter sterilization.
DNase Solution
DNase solution (DS) was 7.5 mg DNase I (Worthington) and 120 ml 45%
glucose solution (Sigma-Aldrich), up to 15 ml with 13 Basal Medium Eagle
media (Invitrogen), followed by 0.22 mm filter sterilization.tember 22, 2015 ª2015 The Authors 1911
Percoll Solution
Percoll (Sigma-Aldrich) was adjusted to a final pH of 7.4 followed by 0.22 mm
filter sterilization. 35% percoll (25 ml 43 PBS-EDTA, 35 ml percoll, and 40 ml
water) and 60% percoll (25 ml 43 PBS-EDTA, 60 ml percoll, 15 ml water, and
300 ml 0.4% trypan blue; Invitrogen) stocks were prepared and stored at 4C.
Cytokines
IL-4, TNF, IFN-g (all eBioscience), IL-13 (Peprotech), and LPS (Sigma-Aldrich)
were used at 10 ng/ml, 10 ng/ml, 2 ng/ml, 40 ng/ml, or 100 ng/ml, respectively.
Anti-mouse IL-13 antibody and IgG1 control (clone MOPC-21) were provided
by Genentech and Bio X Cell, respectively.
TAM Isolation
Solid tumors were excised and minced using a scalpel. Five milliliters of fresh
TDMwas added, transferred to a 50-ml conical tube, and incubated for 20 min
shaking at 37C. Tumor fragments were dissociated with a 10-ml pipet and
passed through a 70-mm strainer. To collect loosely attached cells, the strainer
was then washed with 10 ml PBS. Tumor cells were centrifuged for 5 min at
300 g, 4C, and the supernatant was aspirated. Cells were resuspended in
1 ml fresh DS. Following resuspension, 4 ml PBS was added and cells were
overlaid on a 35%/60% percoll gradient. Percoll gradients with cells were
centrifuged for 20min at 2,000 g, 4C,with the brakes disengaged. Tumor cells
and macrophages were collected from the 35%/60% interphase, transferred
to a 50-ml conical tube containing 10 ml PBS, and centrifuged for 5 min at
300 g, 4C. For RNA preparation of TAMs or TAM populations after cell sorting,
cells were resuspended in MACS buffer with 10% normal mouse serum for
blocking and TAMs were collected by CD11b purification using Miltenyi mag-
netic beads. CD11b+ and CD11b fractions were analyzed by flow cytometry
and/or cytospin.
Flow Cytometry
Cells were resuspended in 200 ml FACS buffer (PBSwith 5%bovine calf serum)
and placed on ice for 15 min to block. Cells were incubated with fluorescently
labeled antibodies on ice in the dark for 20 min and then washed with PBS,
centrifuged at 5003 g for 5 min, resuspended in 200 ml FACS buffer, and eval-
uated on a FACSCanto (Becton Dickinson) flow cytometer. Cell death was
determined using an Annexin V Apoptosis Detection Kit I (BD PharMingen).
Data were further analyzed using FlowJo software (Tree Star).
RNA Isolation and qRT-PCR Analysis
RNAwas collected from TAMs and other cells using Trizol (Invitrogen), accord-
ing to themanufacturer’s protocol. cDNAwas synthesized using SuperScript II
reverse transcriptase (Invitrogen) and analyzed by qRT-PCR using the primer
pairs listed in Supplemental Information. All values were normalized to
GAPDH.
Anti-IL-13 Antibody Treatment
Two hundredmicrograms anti-IL-13 antibody or IgG1 control were injected i.v.
per mouse bearing EG7 thymomas 6 days before tumor harvest.
Etanercept Treatment
EG7 tumor-bearing mice received a daily dose of 0.060 mg/mouse etanercept
(Enbrel) or PBS as control by subcutaneous injection starting 5 days after im-
plantation of the EG7 cells until tumor harvest on day 11.
Statistics
Data indicate themean ±SEMof representative experiments. Statistical signif-
icance was determined by a two-tailed Student’s t test or one-way ANOVA fol-
lowed by Bonferroni post test where indicated in the figure legends using
Graphpad Prism5 justified according to the normality and variance of the dis-
tribution (*p < 0.05; **p < 0.01; ***p < 0.001). Sample size for adequate power
was estimated using preliminary studies.
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